Glaukos Submits New Drug Application to U.S. FDA for Epioxa™ - Yahoo Finance
Glaukos submitted an NDA to the FDA for Epioxa, a non-invasive corneal cross-linking therapy for keratoconus, aiming to reduce procedure times, improve comfort, and shorten recovery. The submission includes data from two successful Phase 3 trials.
Highlighted Terms
Related News
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™ - Yahoo Finance
Glaukos submitted an NDA to the FDA for Epioxa, a non-invasive corneal cross-linking therapy for keratoconus, aiming to reduce procedure times, improve comfort, and shorten recovery. The submission includes data from two successful Phase 3 trials.